市場調査レポート

神経変性疾患における取引の分析

Analysis of Deals in Neurodegenerative Diseases

発行 IMS World Publications Ltd. 商品コード 127549
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
神経変性疾患における取引の分析 Analysis of Deals in Neurodegenerative Diseases
出版日: 2010年07月30日 ページ情報: 英文

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、アルツハイマー病、パーキンソン病、多発性硬化症、てんかん、片頭痛などの神経変性疾患の概要と市場規模、現在の治療法と開発中の製品動向とともに、種類別、開発段階別、製品別の取引動向についてまとめ、概略下記の内容でお届けいたします。

第1章 神経変性疾患のイントロダクション

  • 概要
  • 神経変性疾患取引における全体的動向
    • 他の治療分野との比較
    • 取引件数
    • 取引額
  • 主な参入企業
  • テリトリー別取引
  • 金融危機の影響
  • ロイヤルティ

第2章 アルツハイマー病

  • 概要
    • 疫学
    • 市場規模
    • 現在の治療法
    • 将来の治療法:開発中の製品
  • アルツハイマー病における取引動向
    • 概要
    • 種類別
    • 開発段階別
    • 製品別
    • 参入企業

第3章 パーキンソン病

  • 概要
    • 疫学
    • 市場規模
    • 現在の治療法
    • 将来の治療法:開発中の製品
  • パーキンソン病における取引動向
    • 概要
    • 種類別
    • 開発段階別
    • 製品別
    • 参入企業

第4章 多発性硬化症

  • 概要
    • 疫学
    • 市場規模
    • 現在の治療法
    • 将来の治療法:開発中の製品
  • 多発性硬化症における取引動向
    • 概要
    • 種類別
    • 開発段階別
    • 製品別
    • 参入企業

第5章 てんかん

  • 概要
    • 疫学
    • 市場規模
    • 現在の治療法
    • 将来の治療法:開発中の製品
  • てんかんにおける取引動向
    • 種類別
    • 開発段階別
    • 製品別
    • 参入企業

第6章 片頭痛

  • 概要
    • 疫学
    • 市場規模
    • 現在の治療法
    • 将来の治療法:開発中の製品
  • 片頭痛における取引動向
    • 種類別
    • 開発段階別
    • 製品別
    • 参入企業

第7章 結論

第8章 付録1:アルツハイマー病

第9章 付録2:パーキンソン病

第10章 付録3:多発性硬化症

第11章 付録4:てんかん

第12章 付録4:片頭痛

図表

目次

Abstract

This new report follows the highly acclaimed and popular report series on key deal making therapy areas. It focuses on the five major neurodegenerative diseases:

  • Alzheimer' s disease
  • Parkinson' s disease
  • Multiple sclerosis
  • Epilepsy
  • Migraine

The report contains analysis of deals by deal and product type, number of deals year on year and the value and stage of development of these deals. It looks at the key players and includes case studies of the key deals being made within the five neurodegenerative diseases.

All deal data in this report are taken from the world-leading PharmaDealsR v2 Agreements database.

Table of Contents

1 Introduction to neurodegenerative diseases

  • 1.1 Overview
  • 1.2 Overall trends in neurodegenerative disease deals
    • 1.2.1 Comparison with other therapy areas
    • 1.2.2 Number of deals
    • 1.2.3 Value of deals
  • 1.3 Key players
  • 1.4 Deals by territory
  • 1.5 Impact of the ' credit crunch'
  • 1.6 Royalties

2 Alzheimer' s disease

  • 2.1 Overview
    • 2.1.1 Epidemiology
    • 2.1.2 Market size
    • 2.1.3 Current therapies
    • 2.1.4 Future treatments - products in development
  • 2.2 Trends in deal making in Alzheimer' s disease
    • 2.2.1 Overview
    • 2.2.2 Analysis of deals by deal type
    • 2.2.3 Deals by stage of development
    • 2.2.4 Deals by product type
    • 2.2.5 Key players

3 Parkinson' s Disease

  • 3.1 Overview
    • 3.1.1 Epidemiology
    • 3.1.2 Market size and trends
    • 3.1.3 Current therapies
    • 3.1.4 Future treatments - products in development
  • 3.2 Trends in deal making in Parkinson' s disease
    • 3.2.1 Analysis of deals by deal type
    • 3.2.2 Deals by stage of development
    • 3.2.3 Deals by product type
    • 3.2.4 Key players

4 Multiple sclerosis

  • 4.1 Overview
    • 4.1.1 Epidemiology
    • 4.1.2 Market size and trends
    • 4.1.3 Current therapies
    • 4.1.4 Future treatments - products in development
  • 4.2 Trends in deal making in Multiple sclerosis
    • 4.2.1 Analysis of deals by deal type
    • 4.2.2 Deals by stage of development
    • 4.2.3 Deals by product type
    • 4.2.4 Key players

5 Epilepsy

  • 5.1 Overview
    • 5.1.1 Epidemiology
    • 4.1.2 Market size and trends
    • 4.1.3 Current therapies
    • 5.1.4 Future treatments - products in development
  • 5.2 Trends in deal making in Epilepsy
    • 5.2.1 Analysis of deals by deal type
    • 5.2.2 Deals by stage of development
    • 5.2.3 Key players

6 Migraine

  • 6.1 Overview
    • 6.1.1 Epidemiology
    • 6.1.2 Market size and trends
    • 6.1.3 Current therapies
    • 6.1.4 Future treatments - products in development
  • 6.2 Trends in deal making in Migraine
    • 6.2.1 Analysis of deals by deal type
    • 6.2.2 Deals by stage of development
    • 6.2.3 Key players

7 Conclusions

8 Appendix 1: Alzheimer' s disease deals

  • 8.1 J&J and Elan
  • 8.2 TorreyPines and Eisai
  • 8.3 Medivation and Pfizer
  • 8.4 Myriad Genetics and Lundbeck
  • 8.5 CoMentis and Astellas
  • 8.6 Ablynx and Boehringer

9 Appendix 2: Parkinson' s Disease deals

  • 9.1 Newron Pharmaceuticals and Serono
  • 9.2 Biovail and Acadia

10 Appendix 3: Multiple sclerosis deals

  • 10.1 Facet Biotech and Abbott
  • 10.2 Bayer Schering and Genzyme
  • 10.3 BioMS Medical Corp and Eli Lilly
  • 10.4 Acorda Therapeutics and Biogen Idec
  • 10.5 Fast Forward LLC and Merck Serono

11 Appendix 4: Epilepsy deals

  • 11.1 Valeant and GSK
  • 11.2 BIAL Group and Separacor

12 Appendix 4: Migraine deals

  • 12.1 Pozen and GSK

Tables

  • 1 Prevalence rates for dementia by age group
  • 2 Main drugs currently marketed for AD
  • 3 Products in Phase III development for AD
  • 4 Selected AD deals
  • 5 AD drugs providing symptomatic relief
  • 6 Potentially disease-modifying AD agents
  • 7 Diagnostics
  • 8 Top AD dealmakers (1996 to 2009)
  • 9 Pfizer/Wyeth late stage AD pipeline
  • 10 Top AD principal/orginator organisations (1996 to 2009)
  • 11 Elan' s involvement in later stage AD drugs
  • 12 Products in Phase III development for PD
  • 13 Top PD dealmakers (1996 to 2009)
  • 14 Top PD principal/originator organisations (1996 to 2009)
  • 18 Biogen Idec' s MS pipeline portfolio
  • 19 Products in later stage development for epilepsy
  • 20 Top epilepsy dealmakers (1996 to 2009)
  • 21 Top epilepsy principal/originator organisations (1996 to 2009)
  • 22 Products in later stage development for migraine
  • 23 Top migraine dealmakers (1996 to 2009)

Figures

  • 1 Deal intensity by therapeutic area (1996 to 2009)
  • 2 Number of deals in five neurodegenerative disease areas (1996 to 2009)
  • 3 Value of deals in five neurodegenerative disease areas (1996 to 2009)
  • 3 Value of deals in five neurodegenerative disease areas (1996 to 2009)
  • 4 Number of deals by territory in five neurodegenerative disease areas (1996 to 2009)
  • 5 Impact of the credit crunch on deal-making
  • 6 Disclosed royalty rates for selected neurodegenerative diseases deals
  • 7 2009 worldwide sales of AD drugs (US$ M)
  • 8 total AD deals by deal type
  • 9 Year on year analysis by deal type
  • 10 Deal type by value
  • 11 Number of AD deals by stage of development
  • 12 Average value of AD deals by stage of development
  • 13 Total PD deals by deal type
  • 14 Year on year analysis by deal type
  • 15 Deal type by value
  • 16 Number of PD deals by stage of development
  • 17 Average value of PD deals by stage of development
  • 18 2009 worldwide sales of MS drugs (IUS$M)
  • 19 Total MS deals by deal type
  • 20 Year on year analysis by deal type
  • 21 Deal type by value
  • 22 Number of MS deals by stage of development
  • 23 Average value of MS deals by stage of development
  • 24 Total epilepsy deals by deal type
  • 25 Deal type by value
  • 26 Number of epilepsy deals by stage of development
  • 27 Total migraine deals by deal type
  • 28 Number of migraine deals by stage of development
  • 29 Average value of migraine deals by stage of development
Back to Top